8-K: Collegium Pharma Projects Strong 2026 Growth, Refinances Debt

Collegium Pharmaceutical, Inc. announced its 2026 financial guidance, projecting increased product revenues and adjusted EBITDA, alongside a significant debt refinancing.

Summary

• Collegium Pharmaceutical, Inc. provided its full-year 2026 financial guidance, expecting product revenues, net, in the range of $805 million to $825 million.
• Jornay PM net revenue is projected to be between $190 million and $200 million for 2026, representing a 32% year-over-year growth at the midpoint.
• Adjusted EBITDA for 2026 is anticipated to be in the range of $455 million to $475 million.
• The company successfully closed a new $980 million syndicated credit facility in late December 2025, which was used to repay the remaining $581 million of its previous term loan.
• The new credit facility includes a $580 million senior secured term loan, a $300 million delayed draw term loan, and a $100 million revolving credit facility, with the latter two currently undrawn and available for general corporate purposes, including future business development.
• New supply and quality agreements were entered into with Hikma Pharmaceuticals USA Inc. for authorized generic versions of Nucynta and Nucynta ER.
• Hikma is expected to launch authorized generic versions of Nucynta ER in Q1 2026 and Nucynta by December 2026 or upon the launch of a third-party generic equivalent.
• Collegium will receive a significant share of net profits from the authorized generic products, which will decline based on the number of third-party generic equivalents sold.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook, with strong 2026 financial guidance showing growth, particularly from Jornay PM. The successful debt refinancing improves financial flexibility and reduces interest costs. Strategic plans for capital deployment and business development are clearly articulated, indicating a proactive management approach. The only minor caveat is the upcoming generic competition for Nucynta, though mitigated by authorized generic agreements.

Positives

• Projected 2026 product revenues of $805M-$825M represent growth over the 2025 guidance of $775M-$785M.
• Jornay PM is expected to be a significant growth driver, with projected net revenue of $190M-$200M in 2026, a 32% increase from 2025 guidance.
• The successful refinancing of debt with a new $980 million syndicated credit facility immediately results in meaningful annualized interest savings.
• The new credit facility provides $400 million in undrawn capital (delayed draw term loan and revolving credit facility) for future business development and general corporate purposes.
• The company is on track to achieve its recently increased financial guidance for 2025, indicating strong operational performance.
• Authorized generic agreements for Nucynta and Nucynta ER are expected to maintain meaningful revenues for the Nucynta franchise in 2026 and beyond, despite impending generic competition.

Risks

• Unknown liabilities could materially affect financial results.
• Uncertainty exists regarding the expected financial performance of products and future market opportunities.
• Ability to commercialize and grow sales of products may be impacted by various factors.
• Managing relationships with licensors is crucial for product portfolio success.
• The success of competing products could negatively affect market share and revenue.
• Maintaining regulatory approval for products, including any restrictions or warnings, is essential.
• The size of product markets and the ability to service them could impact growth.
• Obtaining reimbursement and third-party payor contracts for products is critical for market access.
• The rate and degree of market acceptance of products may vary.
• Commercialization costs, including marketing, sales, and distribution, could be higher than anticipated.
• Changing market conditions for products could affect demand and pricing.
• The outcome of any patent infringement or other litigation, or governmental investigations, could be adverse.
• Securing adequate supplies of active pharmaceutical ingredients and manufacturing commercially saleable inventory is vital.
• Ability to obtain funding for operations and business development may be constrained.
• Regulatory developments in the U.S. could impact product approvals or market access.
• Maintaining sufficient intellectual property protection for products is a continuous challenge.
• Compliance with stringent U.S. and foreign government regulations, including DEA compliance, is complex and costly.
• Customer concentration could pose a risk to revenue stability.
• Accuracy of estimates regarding expenses, revenue, capital requirements, and need for additional financing is subject to uncertainty.

Future Outlook

The company projects continued topline revenue growth in 2026, primarily driven by the strong performance of Jornay PM. Management intends to execute a disciplined capital deployment strategy that balances debt repayment, opportunistic share repurchases, and active evaluation of business development opportunities to expand and diversify its portfolio.

Management Comments

• "2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success." Vikram Karnani, President and Chief Executive Officer.
• "The outstanding performance of Jornay PM, along with sustained revenue growth across our pain portfolio, has put us in a strong financial position as we enter the year ahead." Vikram Karnani, President and Chief Executive Officer.
• "We remain dedicated to supporting patients with serious medical conditions while delivering value to our shareholders through strong commercial execution, strategic business development, and disciplined capital deployment." Vikram Karnani, President and Chief Executive Officer.
• "On track to achieve our recently increased financial guidance for 2025 and expect additional topline revenue growth in 2026 to be driven largely by increasing Jornay PM sales." Colleen Tupper, Chief Financial Officer.
• "We look forward to executing our capital deployment strategy which balances paying down debt, opportunistically repurchasing shares, and actively evaluating opportunities to expand and diversify our portfolio through business development." Colleen Tupper, Chief Financial Officer.

Industry Context

Collegium Pharmaceutical operates in the specialized areas of pain management and neuropsychiatry, with a focus on abuse-deterrent opioid formulations and differentiated ADHD treatments. The strong growth projected for Jornay PM highlights the demand for innovative solutions in the ADHD market. The strategic management of its pain portfolio, including authorized generic agreements for Nucynta, reflects a common industry approach to maximize value from mature products while transitioning to new growth drivers. The debt refinancing improves the company's financial flexibility, a key competitive advantage in the capital-intensive pharmaceutical sector, enabling further strategic investments and business development.

Comparison to Industry Standards

• Jornay PM is positioned as the #1 highest rated branded ADHD medicine in terms of product differentiation, indicating strong market perception within its category.
• Belbuca is rated as the #1 highest rated branded ER opioid in terms of product differentiation and favorability, suggesting a leading position in its specific pain management segment.
• The company's projected 2026 product revenue growth and Adjusted EBITDA align with a growth-oriented biopharmaceutical company, particularly one with a rapidly expanding neuropsychiatry business like Jornay PM.

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth, disciplined capital deployment (including share repurchases), and improved financial flexibility from debt refinancing.
• Patients: Continued access to differentiated medicines for serious medical conditions, including responsible pain management and ADHD treatments.
• Employees: Fostering an engaging, collaborative, and respectful corporate culture, as part of the company's commitment to investing in its people.
• Creditors: Strengthened balance sheet and reduced interest rates from the new credit facility, indicating improved creditworthiness and debt management.
• Customers (HCPs): Continued availability of highly differentiated products like Jornay PM, Belbuca, and Xtampza ER, supported by commercial execution.

Next Steps

• Report full-year 2025 annual results in February 2026.
• Hikma Pharmaceuticals to launch authorized generic versions of Nucynta ER in Q1 2026.
• Hikma Pharmaceuticals to launch authorized generic versions of Nucynta by December 2026 or upon the launch of a third-party generic equivalent.
• Continue to drive significant growth for Jornay PM through increased awareness and adoption, and maintaining broad patient access.
• Maximize the durability of the Pain Portfolio.
• Strategically deploy capital through business development, debt repayment, and share repurchases.

Key Dates

Recommendation

Collegium Pharmaceutical demonstrates strong operational momentum with robust 2026 financial guidance, driven by the significant growth of Jornay PM and sustained performance across its pain portfolio. The successful refinancing of debt at a reduced rate enhances financial flexibility and provides substantial capital for future strategic initiatives, including business development and share repurchases. The company's commitment to disciplined capital deployment and a diversified portfolio, coupled with its track record of exceeding guidance, positions it favorably for continued value creation. The positive outlook and strategic financial management make it an attractive investment.

Keywords

Collegium Pharmaceutical, COLL, Financial Guidance, 2026 Outlook, Product Revenue, Adjusted EBITDA, Jornay PM, ADHD, Pain Management, Nucynta, Nucynta ER, Authorized Generic, Debt Refinancing, Credit Facility, Biopharmaceutical, Pharmaceuticals, SEC Filing, 8-K